Diphtheria and Tetanus Vaccine (Adsorbed) I.P.
For the prevention of diphtheria and tetanus in children less than 7 years of age when pertussis antigens is contraindicated or should not be used.
Intramuscular Injection
First 3 doses of 0.5 ml each should be given 4 weeks apart and followed by fourth dose given approximately 6–12 months later
Each single 0.5 ml dose contains
Diphtheria Toxoid ≤ 25 Lf (≥ 30 IU)
Tetanus Toxoid ≥ 5 Lf (≥ 40 IU)
Adsorbed on Aluminium Phosphate, Al+++ ≤ 1.25 mg
Preservative: 0.005% Thiomersal
Box of 10 ampoules of 0.5 ml each
Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (Adsorbed) I.P.
For the prevention of serious childhood diseases: Diphtheria, Tetanus, Pertussis (whooping cough), Hepatitis B and Haemophilus Influenzae type b.
Intramuscular Injection.
First dose is given at 6 weeks or 10 weeks or 14 weeks of age
Second dose is given anytime between 12-18 months of age
Each dose of 0.5 ml contains
Diphtheria Toxoid ≤ 25 Lf (≥ 30 IU)
Tetanus Toxoid ≥ 2.5 Lf (≥ 40 IU)
B. pertussis (whole cell) ≤ 16 OU (≥ 4.0 IU)*
HBsAg (rDNA) ≥ 10 mcg
Purified capsular Hib Polysaccharide (PRP)
Conjugated to Tetanus Toxoid (carrier protein) 10 mcg
+++ Adsorbed on Aluminium Phosphate, Al ≤ 1.25 mg
Preservative: Thiomersal 0.005%
*The lower fiducial limit (P=0.95) of the estimated potency is not less than 2.0 IU. Adsorbed can be given at the age of 15-18 months.
DTPHHVAC SD: 1 dose vial of 0.5 ml
DTPHHVAC PFS: 1 x 0.5 ml - 1 dose pre-filled syringe
Hepatitis B Vaccine (rDNA) I.P.
Hepatitis B vaccine is indicated for active immunization against Hepatitis B infection in subjects considered at risk of exposure to HBV positive material.
Intramuscular Injection.
Pediatric dose vaccine: 10 mcg dose (in 0.5 ml suspension) is recommended for neonates, infants, children and adolescents up to 19 years of age.
Adult dose vaccine: 20 mcg dose (1.0 ml suspension) is recommended for adults aged 20 years and above
A series of 3 shots can prevent this serious disease
6, 10, 14 weeks for infants
0, 1, 6 months for children, adolescents and adults
0, 1, 2 months (for rapid protection)
Each ml dose contains
Purified Hepatitis-B surface antigen 20 mcg
Adsorbed on Aluminium hydroxide, Al+++ ≤ 1.25 mg
Preservative: ≤ 0.01% Thiomersal
Box of 10 ampoules of 0.5 ml each
Box of 10 ampoules of 1 ml each
Box of one 10 ml MD vial
Rabies Vaccine, Human I.P. (Freeze-dried)
RABIESVAC-F is indicated for the prevention of rabies in children and adults. It can be used before or after exposure, as a primary immunization or as a booster dose.
Intramuscular & Intra-dermal.
The following schedule should be followed for pre-exposure prophylaxis in high risk populations.
Route | Dose | Number of doses | Schedule |
---|---|---|---|
Intramuscular | 1 ml | 3 | Day 0, 7 & 21 or 28 |
Intradermal | 0.1 ml | 3 | Day 0, 7 & 21 or 28 |
The following schedule should be followed for post-exposure prophylaxis in previously unimmunized individuals.
Route | Dose | Number of doses | Schedule |
---|---|---|---|
Intramuscular | 1 ml | 5 | Day 0, 3, 7, 14 & 28 |
Intradermal | 0.1 ml | 4 | Day 0, 3, 7 & 28 |
In case an individual who has been fully immunized in the past is exposed to Rabies, the recommended PEP schedule is one dose of Rabies vaccine injected intramuscularly (1 ml) or intradermally (0.1 ml) on day 0 and day 3
1 dose - 1 ml vial plus diluent
Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed) I.P
Indicated for infants above the age of six weeks and of pre-school children against diphtheria, tetanus and pertussis (whooping cough).
Intramuscular Injection
First 3 doses should be given 4 weeks apart at 6, 10 and 14 weeks.
A booster dose can be given at the age of 15-18 months and also between the ages of 4 to 6 years.
Each single 0.5 ml dose contains
Diphtheria Toxoid ≤ 25 Lf (≥ 30 IU)
Tetanus Toxoid ≥ 5 Lf (≥ 40 IU)
B. Pertussis ≤ 16 OU (≥ 4 IU)
Adsorbed on Aluminium Phosphate, Al+++ ≤ 1.25 mg
Preservative: 0.005% Thiomersal
Box of 10 ampoules of 0.5 ml each
Box of 10 MD vials of 5 ml each